Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2016-08-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-016-1879-5PMID 27497816PMCID PMC11029746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resource GM-CSF Mouse Bone Mar row Cultures Comprise a Heterogeneous Population of CD 11 c + MHCII + Macrophages and Dendritic Cells Highlights

  2015cited by this paper
• PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

  2014cited by this paper
• A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

  2014cited by this paper
• Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen

  2013cited by this paper
• Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells.

  2012cited by this paper
• Hypoxia-inducible factor-1 alpha–dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa

  2012cited by this paper
• Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

  2011cited by this paper
• Angiogenic signaling aberrantly induced by tumor hypoxia.

  2011cited by this paper
• HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells

  2011cited by this paper
• Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.

  2011cited by this paper
• Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response.

  2011cited by this paper
• Targeting hypoxia in cancer therapy

  2011cited by this paper
• Cytotoxic T cells - stroma interactions.

  2011cited by this paper
• Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

  2010cited by this paper
• The Cooperative Induction of Hypoxia-Inducible Factor-1α and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis12

  2009cited by this paper
• T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.

  2009cited by this paper
• A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

  2008cited by this paper
• Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

  2008cited by this paper
• Targeted Deletion of HIF-1α Gene in T Cells Prevents their Inhibition in Hypoxic Inflamed Tissues and Improves Septic Mice Survival

  2007cited by this paper
• Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

  2007cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Effects of hypoxia on tumor metabolism

  2007cited by this paper
• Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors

  2005cited by this paper
• Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors.

  2005cited by this paper
• Glycobiology and Cancer: Meeting Summary and Future Directions

  2004cited by this paper
• Exploiting tumour hypoxia in cancer treatment

  2004cited by this paper
• Small Molecule-Mediated Anti-Cancer Therapy via Hypoxia Inducible Factor-1 Blockade

  2004cited by this paper
• Hypoxia-inducible factor-1 in tumour angiogenesis.

  2004cited by this paper
• Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

  2004cited by this paper
• Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α

  2004cited by this paper
• Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• Differential Effects of Physiologically Relevant Hypoxic Conditions on T Lymphocyte Development and Effector Functions

  2001cited by this paper
• Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo

  1993cited by this paper

• Optimizing mitochondria function in immune cells: implications for cancer immunotherapy.

  2025cites this paper
• Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors

  2025cites this paper
• Hypoxia-inducible factors in breast cancer: prognostic indicators and emerging biomarkers: narrative review

  2025cites this paper
• Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy.

  2025cites this paper
• Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies

  2025cites this paper
• Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications

  2025cites this paper
• Associations between HIFs and tumor immune checkpoints: mechanism and therapy

  2024cites this paper
• Mathematical modeling of hypoxia and adenosine to explore tumor escape mechanisms in DC-based immunotherapy

  2024influential citation
• Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments

  2024cites this paper
• Recent advances in immunotherapy-involved combination cancer therapy based on ZIF-8

  2024cites this paper
• Mechanisms of HIF-driven immunosuppression in tumour microenvironment

  2023cites this paper
• Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway

  2023cites this paper
• Dual ligand-assisted assembly of metal-organic frameworks on upconversion nanoparticles for NIR photodynamic therapy against hypoxic tumors.

  2023cites this paper
• Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.

  2022cites this paper
• Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice

  2022cites this paper
• CD73 Molecule Inhibitor Upregulates miR16 Expression in Experimental Glioblastoma and Inhibits Angiogenesis by Targeting VEGF

  2022cites this paper
• Construction and evaluation of a prognostic risk assessment model of gastric cancer by using hypoxia features.

  2022cites this paper
• Hypoxia, a key factor in the immune microenvironment.

  2022cites this paper
• Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line.

  2022cites this paper
• Understanding the Crosstalk Between Epigenetics and Immunometabolism to Combat Cancer.

  2022cites this paper
• Unraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy.

  2022cites this paper
• Computational biological activity and pharmacological properties analysis for anticancer Cyperus rotundus bioactive compounds

  2021cites this paper
• Perspectives on Hypoxia Signaling in Tumor Stroma

  2021cites this paper
• Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

  2021cites this paper
• 90K predicts the prognosis of glioma patients and enhances tumor lysate-pulsed DC vaccine for immunotherapy of GBM in vitro

  2021cites this paper
• Blockade of HIF-1α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth.

  2021cites this paper
• Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment

  2021cites this paper
• HIF in Nephrotoxicity during Cisplatin Chemotherapy: Regulation, Function and Therapeutic Potential

  2021cites this paper
• Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

  2021cites this paper
• An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach

  2021cites this paper
• The impact of hypoxia on immune state in cancer.

  2021cites this paper
• DCE‐MRI for early evaluation of therapeutic response in esophageal cancer after concurrent chemoradiotherapy and its values in predicting HIF‐1α expression

  2021cites this paper
• A comprehensive review on functional properties of preserved eggs as an excellent food ingredient with anti-inflammatory and anti-cancer aspects

  2021cites this paper
• Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy.

  2021cites this paper
• Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application.

  2021cites this paper
• The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance

  2021cites this paper
• Obesity, Diabetes, and Increased Cancer Progression

  2021cites this paper
• Simultaneous silencing of A2aR and PD-1 as immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models.

  2021cites this paper
• Targeting hypoxia and hypoxia‐inducible factor‐1 in the tumor microenvironment for optimal cancer immunotherapy

  2021cites this paper
• Combined inhibition of CD73 and ZEB1 by Arg-Gly-Asp (RGD)-targeted nanoparticles inhibits tumor growth.

  2020cites this paper
• Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine

  2020cites this paper
• Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression.

  2020cites this paper
• CDK1 in Breast Cancer: Implications for Theranostic Potential.

  2020cites this paper
• PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.

  2020cites this paper
• Optimized Dose of Dendritic Cell-based Vaccination in Experimental Model of Tumor Using Artificial Neural Network.

  2020cites this paper
• Silencing of p68 and STAT3 synergistically diminishes cancer progression.

  2020cites this paper
• Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer.

  2020cites this paper
• Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression.

  2020cites this paper
• Nanomedicine for improvement of dendritic cell-based cancer immunotherapy.

  2020cites this paper
• Coinhibition of S1PR1 and GP130 by siRNA‐loaded alginate‐conjugated trimethyl chitosan nanoparticles robustly blocks development of cancer cells

  2020cites this paper
• Role of dendritic cell metabolic reprogramming in tumor immune evasion.

  2020cites this paper
• Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression.

  2020cites this paper
• Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.

  2020cites this paper
• Inhibition of HIF-1α/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells.

  2020cites this paper
• Immunotherapy in breast cancer: Current status and future directions.

  2019cites this paper
• Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal–Organic Framework Nanoparticles to Boost Cancer Immunotherapy

  2019cites this paper
• Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway.

  2019cites this paper
• Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion

  2019cites this paper
• Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells.

  2019cites this paper
• Potential of CD73 as a target for cancer immunotherapy.

  2019cites this paper
• HIF-1α is a key mediator of the lung inflammatory potential of lithium-ion battery particles

  2019cites this paper
• Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy

  2019cites this paper
• E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions.

  2019cites this paper
• Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer.

  2019cites this paper
• Anti‐angiogenic effects of CD73‐specific siRNA‐loaded nanoparticles in breast cancer‐bearing mice

  2018cites this paper
• High HIF-1α expression predicts poor prognosis of patients with colon adenocarcinoma.

  2018cites this paper
• Mathematical Model of Cancer Immunotherapy by Dendritic Cells Combined with Tumor Hypoxia Treatment

  2018influential citation
• The role of DEAD‐box RNA helicase p68 (DDX5) in the development and treatment of breast cancer

  2018cites this paper
• Rhein enhances the cytotoxicity of effector lymphocytes in colon cancer under hypoxic conditions.

  2018cites this paper
• The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer.

  2018cites this paper
• The impact of metabolic reprogramming on dendritic cell function

  2018cites this paper
• Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium

  2018cites this paper
• Towards superior dendritic-cell vaccines for cancer therapy

  2018cites this paper
• Profiling dendritic cell subsets in head and neck squamous cell tonsillar cancer and benign tonsils

  2018cites this paper
• Correlates of immune and clinical activity of novel cancer vaccines.

  2018cites this paper
• Hypoxia and acidosis: immune suppressors and therapeutic targets

  2018cites this paper
• Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors

  2017cites this paper
• Malignant pheochromocytoma–paraganglioma: pathogenesis, TNM staging, and current clinical trials

  2017cites this paper
• CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice

  2017cites this paper
• Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.

  2017cites this paper
• Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination

  2016cites this paper